| 苯扎贝特致横纹肌溶解文献病例分析 |
| 投稿时间：2024-04-22 修订日期：2024-09-19 点此下载全文 |
| 引用本文： |
| 摘要点击次数: 36 |
| 全文下载次数: 0 |
|
| 基金项目:泰康健投青年医学科研启动基金（2022022） |
|
| 中文摘要:目的：了解苯扎贝特致横纹肌溶解症的临床特点,分析其致不良反应的相关原因,为临床合理应用提供参考。方法：计算机检索国内外数据库(2000年-2023年11月30日),收集苯扎贝特致横纹肌溶解症的病例报告类文献,提取相关基础数据进行统计分析,对符合入选标准的病例进行苯扎贝特用药合理性及不良反应关联性评价。结果：共检测到苯扎贝特致横纹肌溶解的个案报道共26篇,包含28例患者。其中男性10例,女性18例,平均年龄为(64.57±11.20)岁,年龄中位数为65岁。发生不良反应时间为(7.57±4.98)天,中位数为6天。患者除高血脂外均合并有其他疾病,且肌酐清除率普遍小于80ml/min,有16例患者超剂量使用苯扎贝特。结论：苯扎贝特说明书需要国家药品监督管理部门的规范和管理；临床应用苯扎贝特时应注意用药合理性,加强不良反应监测与患者用药教育。 |
| 中文关键词:苯扎贝特 横纹肌溶解 病例 分析 |
| |
| Literature Analysis of Rhabdomyolysis Induced by Bezafibrate |
|
|
| Abstract:Abstract: Objective To analyze the causes of adverse reactions induced by bezafibrate, study the clinical characteristics of rhabdomyolysis, and provide reference for clinical rational use. Methods The case reports of bezafibrate induced rhabdomyolysis were collected from domestic and foreign databases (from 2000 to November 30, 2022), and the relevant basic data were extracted for statistical analysis. The rationality and adverse reaction relevance of bezafibrate use which meets the inclusion criteria were evaluated. Results A total of 26 cases of bezafibrate induced rhabdomyolysis were reported, including 28 patients. There were 10 males and 18 females, with an average age of (64.57±11.20) years and a median age of 65 years. The occurrence time of adverse reaction was (7.57±4.98) days, and the median was 6 days. All patients had other diseases except hyperlipemia. The creatinine clearance rate (CCR) of patients were generally less than 80ml/min. There were 16 patients gaven over-dosed bezafibrate. Conclusion The drug instruction of bezafibrate should be regulated and managed by National Regulatory Authority. In clinical application, attention should be paid to the rationality of medication use, the ADR monitoring and patient education. |
| keywords:Bezafibrate Rhabdomyolysis literature Analysis |
| 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
